Cargando…

Real-world Evaluation of Ceftolozane/Tazobactam (C/T) Use and Clinical Outcomes at an Academic Medical Center in Las Vegas

BACKGROUND: There is a global increase in Gram-negative (GN) pathogens, with Enterobacteriaceae and Pseudomonas aeruginosa(PSA) being the major threats in clinical practice. C/T is a novel antipseudomonal cephalosporin combined with an established β-lactamase inhibitor, approved for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leuthner, Kimberly D, Kullar, Ravina, Jayakumar, Becky, Hewlett, David A, Nguyen, Truong, Puzniak, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632114/ http://dx.doi.org/10.1093/ofid/ofx163.682

Ejemplares similares

Real-world use of ceftolozane/tazobactam: a systematic literature review
por: Puzniak, Laura, et al.
Publicado: (2021)

Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections
por: Puzniak, Laura, et al.
Publicado: (2021)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

2248. Clinical and Microbiological Outcomes Associated with Real-World Use of Ceftolozane/Tazobactam
por: Cabrera, Nicolo, et al.
Publicado: (2019)

1612. Evaluation of the Use of Ceftolozane/Tazobactam for the Treatment of ESBL-producing Enterobacterales Infections Using International Data from SPECTRA (Study of Prescribing Patterns and Effectiveness of Ceftolozane/Tazobactam Real World Analysis)
por: Soriano, Alex, et al.
Publicado: (2020)

2414. Real-World Evaluation of Patient Characteristics and Outcomes of Patients Treated With Ceftolozane/Tazobactam Across 253 US Hospitals
por: Puzniak, Laura, et al.
Publicado: (2018)

Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
por: Khankhel, Z. S., et al.
Publicado: (2022)

Real-world Analysis of Prescribing Patterns and Susceptibility of Ceftolozane/Tazobactam (C/T) Treatment using an Electronic Medical Record (EMR) Database in the United States
por: Pogue, Jason M, et al.
Publicado: (2017)

1625. Real-World Outpatient Utilization of Ceftolozane/Tazobactam in Physician Office Infusion Centers (OICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2020)

2200. Cost-effectiveness of Ceftolozane/Tazobactam for Treating Ventilated Nosocomial Bacterial Pneumonia
por: Naik, Jaesh, et al.
Publicado: (2019)

2279. Study of Prescribing patterns and Effectiveness of Ceftolozane–tazobactam (C/T): Real-world Analysis (SPECTRA): a multi-national, multicenter observational study
por: Soriano, Alex, et al.
Publicado: (2019)

Ceftolozane-tazobactam in nosocomial pneumonia
por: Candel, Francisco Javier, et al.
Publicado: (2022)

Erratum: Ceftolozane-tazobactam in nosocomial pneumonia
por: FJ, Candel, et al.
Publicado: (2022)

2291. Evaluation of Multidrug-Resistant Pseudomonas aeruginosa Isolates in Patients Receiving Ceftolozane/tazobactam
por: Bodo, Emily C, et al.
Publicado: (2019)

Review of Treatment Regimens for Mucormycosis in a Las Vegas County Hospital Between 2013 and 2017
por: Villamagna, Angela, et al.
Publicado: (2017)

PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease
por: Xiao, Alan J., et al.
Publicado: (2016)

1319. Pharmacokinetics of Ceftolozane/Tazobactam in Patients with Burns
por: Hall, Ronald G, et al.
Publicado: (2020)

Ceftolozane-tazobactam: When, how and why using it?
por: López, Inmaculada, et al.
Publicado: (2021)

Retrospective Real-World Evaluation of Outcomes in Patients with Skin and Soft Structure Infections Treated with Tedizolid in an Outpatient Setting
por: Kullar, Ravina, et al.
Publicado: (2020)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
por: Fiore, Marco, et al.
Publicado: (2021)

A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Hart, Delaney E, et al.
Publicado: (2021)

1596. Ceftolozane/tazobactam (Zerbaxa) for the Treatment of Pseudomonas aeruginosa (PSA) Bacteremia: A Systematic Literature Review (SLR)
por: Dillon, Ryan J, et al.
Publicado: (2020)

1282. Ceftolozane/Tazobactam Use in Critically Ill Patients Receiving Intermittent or Continuous Renal Replacement Therapy
por: Henry, Molly, et al.
Publicado: (2021)

Ceftolozane/Tazobactam for Resistant Drugs Pseudomonas aeruginosa Respiratory Infections: A Systematic Literature Review of the Real-World Evidence
por: Giaccari, Luca Gregorio, et al.
Publicado: (2021)

2812. Clinical Impact of the Ceftolozane-Tazobactam Shortage on Difficult-To-Treat Resistant Pseudomonas aeruginosa Infections at an Academic Medical Center
por: Vance, Mary K, et al.
Publicado: (2023)

Ceftolozane-tazobactam for the Treatment of Multi Drug-resistant Pseudomonas aeruginosa (MDRPA) Infections
por: Molnar, Esther, et al.
Publicado: (2017)

1608. Efficacy of Ceftolozane/Tazobactam for Multidrug-Resistant Gram-Negative Infections in Multiple Urban Hospitals
por: Cabrera, Nicolo, et al.
Publicado: (2020)

2281. Ceftolozane–tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients with Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PA) Infections
por: Hart, Delaney E, et al.
Publicado: (2019)

522. In Vitro Antimicrobial Activity of Ceftazidime/Avibactam Compared with Ceftolozane/Tazobactam Against Real-world Clinical Isolates of Pseudomonas aeruginosa at a Large Academic Tertiary Care Hospital
por: Patel, Twisha S, et al.
Publicado: (2019)

Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
por: Naik, Jaesh, et al.
Publicado: (2021)

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
por: Barnes, Melissa D., et al.
Publicado: (2018)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
por: Terracciano, Joseph, et al.
Publicado: (2017)

Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia
por: Ruiz, Jesus, et al.
Publicado: (2020)

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2021)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT
por: Honore, Patrick M., et al.
Publicado: (2022)

In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against Pseudomonas aeruginosa Infection-Isolates from an Academic Medical Center in Thailand
por: Tantisiriwat, Woraphot, et al.
Publicado: (2022)

Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial
por: Lodise, Thomas, et al.
Publicado: (2020)

The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections
por: Caffrey, Aisling R., et al.
Publicado: (2022)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_udc419afhq2ck2opt4tp9jja1l